RFT1: The Man5GlcNAc2-PP-Dolichol Flippase Essential for N-Linked Glycosylation

Introduction

RFT1 (UniProt: Q96AA3) encodes a 541-amino acid integral membrane protein that functions as a lipid-linked oligosaccharide (LLO) flippase in the endoplasmic reticulum (ER). The protein catalyzes the translocation of Man5GlcNAc2-PP-dolichol (M5GN2-PP-Dol) from the cytoplasmic face to the luminal face of the ER membrane, a critical step in the biosynthesis of the oligosaccharide substrate used for N-linked protein glycosylation [helenius-2002-rft1-nature-abstract]. This translocation event represents an essential checkpoint in the dolichol pathway, as the final assembly steps of the 14-sugar N-glycan precursor can only occur within the ER lumen where the mannose and glucose donors (Dol-P-Man and Dol-P-Glc) are available.

The identification of RFT1's function has had a complex scientific history. Initial genetic studies in yeast in 2002 demonstrated that RFT1 is essential for viability and that its depletion results in accumulation of the M5GN2-PP-Dol intermediate on the cytoplasmic face of the ER [helenius-2002-rft1-nature-abstract]. However, subsequent biochemical studies using reconstituted systems challenged whether RFT1 directly catalyzes the flipping reaction or plays an indirect role [frank-2008-rft1-flip-abstract]. This controversy persisted for over two decades until 2024, when a fully reconstituted in vitro assay definitively demonstrated that purified RFT1 directly catalyzes M5GN2-PP-Dol translocation across lipid bilayers [chen-2024-rft1-flippase-abstract].

RFT1 belongs to the MOP (multidrug/oligosaccharidyl-lipid/polysaccharide) exporter superfamily of transporters, which includes the bacterial MurJ flippases that export lipid II for peptidoglycan biosynthesis. Defects in human RFT1 cause RFT1-CDG (formerly CDG-In), a rare congenital disorder of glycosylation characterized by developmental delay, seizures, and sensorineural deafness [haeuptle-2008-rft1-cdg-abstract].

Molecular Function: The LLO Flippase Activity

The primary function of RFT1 is to catalyze the ATP-independent translocation of Man5GlcNAc2-PP-dolichol across the ER membrane. This flippase activity is essential because N-glycan biosynthesis is topologically divided between the two leaflets of the ER membrane. The initial steps of oligosaccharide assembly—adding two GlcNAc residues and five mannose residues to dolichol pyrophosphate—occur on the cytoplasmic face using nucleotide-activated sugar donors (UDP-GlcNAc and GDP-mannose). The subsequent steps—adding four more mannoses and three glucoses—occur in the ER lumen using dolichol-phosphate-linked sugar donors [chen-2024-rft1-flippase-abstract].

The 2024 study by Chen et al. definitively resolved the mechanism question by developing a completely reconstituted in vitro assay. Using proteoliposomes containing purified RFT1 and synthetic M5GN2-PP-Dol substrate, the researchers demonstrated that RFT1 is both necessary and sufficient for translocation [chen-2024-rft1-flippase-abstract]. Key characteristics of the flippase activity include:

1. ATP independence: Translocation occurs without ATP hydrolysis, suggesting a facilitated diffusion or alternating access mechanism rather than active transport.

2. Substrate selectivity: RFT1 demonstrates strong preference for M5GN2-PP-Dol over M3GN2-PP-Dol (the three-mannose intermediate), ensuring that translocation occurs only after the complete heptasaccharide is assembled on the cytoplasmic face.

3. Lipid carrier tolerance: The flippase activity occurs with similar kinetics for both natural dolichol and synthetic phytanol lipid carriers.

4. Functional conservation: The archaeal homolog Agl23 from halophilic archaea can functionally substitute for RFT1 in yeast, demonstrating evolutionary conservation of this essential function [chen-2024-rft1-flippase-abstract].

The Scientific Controversy and Its Resolution

The question of whether RFT1 directly catalyzes LLO flipping was controversial for over twenty years. The initial genetic evidence from Helenius et al. (2002) strongly supported a direct role: yeast cells lacking RFT1 accumulated M5GN2-PP-Dol on the cytoplasmic face and failed to complete N-glycan biosynthesis [helenius-2002-rft1-nature-abstract]. However, subsequent biochemical studies produced contradictory results.

Frank et al. (2008) reported that LLO flipping activity could be detected in reconstituted proteoliposomes that lacked RFT1, leading them to conclude that "a specific ER protein(s), but not Rft1, is required to flip Man5GlcNAc2-PP-Dol in reconstituted vesicles" [frank-2008-rft1-flip-abstract]. Similarly, Rush et al. (2009) found that sealed microsomes prepared from RFT1-depleted yeast cells retained normal M5-DLO flippase activity in vitro, even though the same cells accumulated 37-fold more M5GN2-PP-Dol than wild-type cells in vivo [rush-2009-rft1-microsomes-abstract].

These paradoxical findings suggested that cellular organization might be critical for RFT1 function—that the protein's role might depend on membrane organization, protein complexes, or other factors that are disrupted during cell lysis and microsome preparation. Alternative explanations included the possibility that RFT1 functions indirectly, perhaps by organizing or chaperoning the substrate rather than directly catalyzing translocation.

The controversy was resolved by the 2024 study, which identified several technical factors that had confounded earlier in vitro studies [chen-2024-rft1-flippase-abstract]. The key advance was developing a fully reconstituted system with defined components, including purified RFT1 protein and synthetic M5GN2-PP-Dol substrate, rather than relying on crude microsomal preparations that contained numerous contaminating activities. This approach definitively demonstrated that purified RFT1 catalyzes M5GN2-PP-Dol translocation, confirming its identity as the authentic ER flippase.

Protein Structure and Membrane Topology

Human RFT1 is a polytopic membrane protein with a complex transmembrane architecture. Recent structural predictions using AlphaFold2 reveal that the protein contains 14 transmembrane (TM) spans arranged as two lobes, each containing seven transmembrane helices [pei-2024-rft1-molecular-abstract]. This is in contrast to earlier predictions of 11 transmembrane domains based on hydropathy analysis.

Key structural features include:

1. Nin-Cin topology: Both the N-terminus and C-terminus are oriented toward the cytoplasm, consistent with an even number of transmembrane spans.

2. Central hydrophilic cavity: A cavity approximately 23 Å wide at the membrane-water interface extends into the membrane, presumably providing a translocation pathway for the bulky glycan headgroup.

3. Inward-open conformation: The AlphaFold model resembles the inward-open state of alternating access transporters, suggesting that the protein likely cycles between inward-open (cytoplasm-facing) and outward-open (lumen-facing) conformations during the translocation cycle.

4. Structural similarity to MurJ: The overall architecture resembles bacterial MurJ flippases, which transport lipid II (the peptidoglycan precursor) across the cytoplasmic membrane. Both proteins belong to the MOP transporter superfamily and share the challenge of translocating large, amphipathic lipid-linked substrates [pei-2024-rft1-molecular-abstract].

5. Lack of N-glycosylation: Although human RFT1 contains a potential N-glycosylation sequon in intracellular loop 3, the protein is not N-glycosylated, consistent with this region being oriented toward the cytoplasm rather than the ER lumen.

The human RFT1 protein shares only 22% sequence identity with its yeast ortholog, yet the human protein can functionally complement yeast cells lacking RFT1, demonstrating that the core structural and functional features are evolutionarily conserved [haeuptle-2008-rft1-cdg-abstract].

Subcellular Localization and Tissue Expression

RFT1 localizes to the endoplasmic reticulum membrane, consistent with its function in the ER-localized N-glycosylation pathway [pei-2024-rft1-molecular-abstract]. Fluorescence microscopy studies in yeast using ER marker proteins demonstrate that RFT1 distributes throughout the ER network rather than being restricted to specific ER subdomains. This distribution pattern is consistent with the protein's role in the general N-glycosylation pathway, which operates throughout the ER to modify newly synthesized secretory and membrane proteins.

The ER localization is essential for RFT1 function because the substrate (M5GN2-PP-Dol) is synthesized on the cytoplasmic face of the ER, and the product of translocation is immediately utilized by luminal mannosyltransferases and glucosyltransferases to complete N-glycan biosynthesis.

Interestingly, studies in Trypanosoma brucei have revealed that the RFT1 ortholog (TbRFT1) localizes to both the ER and the Golgi apparatus [gottier-2017-rft1-gpi-abstract]. This dual localization suggests that RFT1 may have additional roles beyond ER-localized LLO flipping, at least in some organisms. However, whether human RFT1 similarly localizes to the Golgi remains to be determined.

With respect to tissue distribution, data from the Human Protein Atlas demonstrates that RFT1 exhibits low tissue specificity, being expressed in all examined human tissues [human-protein-atlas]. The mRNA expression shows relatively uniform distribution (Tau score of 0.23), with highest expression observed in pancreas (21.1 nTPM), lymph nodes (15.7 nTPM), and endocrine tissues such as parathyroid and thyroid glands (13.7-14.6 nTPM). Skeletal muscle shows the lowest expression (4.6 nTPM), while brain regions display moderate levels (4.4-7.6 nTPM). This ubiquitous expression pattern is consistent with RFT1's essential role in N-linked glycosylation, a fundamental process required for the maturation of secretory and membrane proteins in all cell types.

Position in the N-Glycosylation Pathway

N-linked glycosylation is the most common covalent modification of proteins in eukaryotic cells, with profound implications for protein folding, quality control, trafficking, and function [helenius-2004-nglycans-review-abstract]. The glycans serve multiple roles in the ER: they promote proper folding by stabilizing polypeptide structures, act as recognition tags for lectins and chaperones, and signal whether proteins have achieved their native conformation or should be targeted for degradation via ER-associated degradation (ERAD). The transfer of the pre-assembled oligosaccharide from its dolichol carrier to nascent proteins is mediated by the oligosaccharyltransferase (OST) complex at the ER translocon, ensuring that glycosylation occurs co-translationally.

RFT1 occupies a central position in the dolichol pathway of N-linked glycosylation, acting at the boundary between cytoplasmic and luminal biosynthetic steps:

Upstream enzymes (cytoplasmic face):
- DPAGT1: Transfers GlcNAc-1-P to dolichol-P
- ALG13/ALG14: Adds second GlcNAc
- ALG1: Adds first mannose (α1,4)
- ALG2: Adds mannoses 2 and 3 (α1,3 and α1,6)
- ALG11: Adds mannoses 4 and 5 (α1,2)

The RFT1 translocation step:
M5GN2-PP-Dol is flipped from the cytoplasmic to the luminal face of the ER membrane.

Downstream enzymes (luminal face):
- ALG3: Adds mannose 6 (α1,3)
- ALG9: Adds mannose 7 (α1,2)
- ALG12: Adds mannose 8 (α1,6)
- ALG9: Adds mannose 9 (α1,2)
- ALG6, ALG8, ALG10: Add three glucose residues

Final transfer:
The oligosaccharyltransferase (OST) complex transfers the completed Glc3Man9GlcNAc2 oligosaccharide from dolichol to asparagine residues in nascent polypeptides within the consensus sequence Asn-X-Ser/Thr.

The strict substrate selectivity of RFT1 for the M5 intermediate (rather than shorter intermediates) ensures that translocation occurs only after the cytoplasmic biosynthetic steps are complete. This checkpoint function prevents premature translocation that would result in truncated, non-functional glycan structures [chen-2024-rft1-flippase-abstract].

Broader Roles in Glycosylation

While the primary function of RFT1 is in the N-glycosylation pathway, recent evidence suggests that RFT1 may influence other glycosylation processes. A study in Trypanosoma brucei, where RFT1 is non-essential and can be completely deleted (unlike in yeast and mammals), revealed that TbRFT1 deficiency affects not only N-glycosylation but also glycosylphosphatidylinositol (GPI) anchor side-chain modification [gottier-2017-rft1-gpi-abstract].

Analysis of GPI-anchored proteins in TbRFT1-null parasites demonstrated truncated GPI anchor side chains compared to wild-type cells. Importantly, this GPI underglycosylation was not due to defective formation of GPI precursor lipids or impaired galactosylation in the ER. Rather, the defect appeared to occur at modifications expected to take place in the Golgi apparatus. Consistent with this, TbRFT1 was found to localize to both the ER and Golgi by immunofluorescence microscopy [gottier-2017-rft1-gpi-abstract]. These findings implicate RFT1 in a broader range of glycosylation processes than previously appreciated, though whether this expanded role applies to human RFT1 remains to be determined.

The connection between N-glycosylation and GPI anchor biosynthesis is not entirely surprising, as both pathways share the use of dolichol-linked sugar donors and involve similar topological challenges of transporting glycolipid intermediates across membranes. The observation that RFT1 affects GPI glycosylation in T. brucei raises the possibility that some aspects of the clinical phenotype in RFT1-CDG patients may relate to GPI anchor defects in addition to N-glycosylation abnormalities.

Evolutionary Conservation

RFT1 is highly conserved across eukaryotes and has functional orthologs in archaea, reflecting the ancient origin of N-linked glycosylation. Key observations regarding conservation include:

1. Eukaryotic conservation: RFT1 orthologs are found in all examined eukaryotes, from yeast to humans. Despite only 22% sequence identity between human and yeast RFT1, the proteins are functionally interchangeable—human RFT1 complements yeast rft1Δ mutants [haeuptle-2008-rft1-cdg-abstract].

2. Archaeal orthologs: Archaea also assemble N-glycans on dolichol-linked carriers and possess RFT1 homologs. The archaeal protein Agl23 from Haloferax halobium can suppress rft1Δ lethality in yeast and exhibits M5GN2-PP-Dol flipping activity, demonstrating functional conservation across domains of life [chen-2024-rft1-flippase-abstract].

3. MOP superfamily membership: RFT1 belongs to the oligosaccharidyl-lipid flippase (OLF) family within the broader MOP transporter superfamily. This superfamily includes the bacterial MurJ lipid II flippases, suggesting that lipid-linked oligosaccharide translocation mechanisms evolved from a common ancestor.

Clinical Significance: RFT1-CDG

Defects in human RFT1 cause RFT1-CDG (OMIM 612015), a rare autosomal recessive disorder formerly known as CDG-In. This condition was first described in 2008 when Haeuptle et al. identified a patient with a homozygous c.199C>T mutation (p.R67C) in RFT1 [haeuptle-2008-rft1-cdg-abstract].

Clinical features of RFT1-CDG typically include:
- Developmental delay and intellectual disability
- Hypotonia
- Seizures, often presenting as early-onset epileptic encephalopathy [aeby-2016-rft1-epilepsy-abstract]
- Sensorineural deafness (a distinctive feature that helps distinguish RFT1-CDG from other CDG subtypes) [vleugels-2009-rft1-novel-cdg-abstract]
- Hepatomegaly and coagulopathy
- Dysmorphic features

Cellular pathology: At the cellular level, RFT1 deficiency causes accumulation of DolPP-GlcNAc2Man5 on the cytoplasmic face of the ER and a corresponding reduction in the complete DolPP-GlcNAc2Man9Glc3 oligosaccharide in the lumen. This results in hypoglycosylation of many secretory and membrane proteins, as the oligosaccharyltransferase cannot efficiently transfer incomplete glycan structures [haeuptle-2008-rft1-cdg-abstract].

Known mutations: To date, multiple pathogenic RFT1 mutations have been identified, including:
- p.R67C (in a hydrophilic loop)
- p.R25W, p.C70R (N-terminal region)
- p.K152E (luminal loop)
- p.G276D, p.E298K (luminal loops)
- p.M408V, p.R442Q (transmembrane domains) [pei-2024-rft1-molecular-abstract]

Analysis of disease mutations reveals that most map to highly conserved regions of the protein, particularly the central hydrophilic cavity that likely forms the substrate translocation pathway. Mutations in the transmembrane domains appear to be associated with milder phenotypes compared to mutations in the luminal loops [pei-2024-rft1-molecular-abstract].

Diagnosis and treatment: RFT1-CDG is diagnosed through a combination of transferrin isoelectric focusing (which shows a type I CDG pattern), cellular LLO analysis (showing M5GN2-PP-Dol accumulation), and confirmatory genetic testing. Currently, no specific treatment exists for RFT1-CDG; management is symptomatic and supportive, focusing on seizure control, developmental support, and management of other complications.

Open Questions

Despite significant advances in understanding RFT1 function, several important questions remain:

1. Detailed translocation mechanism: While it is now established that RFT1 catalyzes M5GN2-PP-Dol translocation, the precise molecular mechanism remains unclear. Does RFT1 function as a true flippase with an alternating access mechanism, or does it create a channel or groove that allows the lipid-linked oligosaccharide to traverse the membrane? High-resolution structural studies of RFT1 in different conformational states are needed.

2. Energetics of translocation: How does RFT1 catalyze the thermodynamically unfavorable movement of a large, hydrophilic glycan headgroup across the hydrophobic membrane core without ATP hydrolysis? Understanding whether translocation is driven by substrate concentration gradients, membrane potential, or other factors remains an open question.

3. In vivo regulation: Little is known about how RFT1 activity is regulated in cells. Is the protein subject to post-translational modification? Does it form functional complexes with other glycosylation machinery components? Does RFT1 expression or activity change in response to ER stress or glycosylation demands?

4. Genotype-phenotype correlations: With relatively few RFT1-CDG patients identified to date, the relationship between specific mutations and clinical severity remains incompletely defined. Why do some mutations (e.g., transmembrane domain mutations) appear to cause milder disease than others?

5. Therapeutic opportunities: Could RFT1-CDG be treated by approaches that enhance residual RFT1 activity, bypass the translocation step, or supplement glycosylation through alternative pathways? Understanding the degree of residual function in different mutations could inform therapeutic strategies.

6. Resolution of the in vitro paradox: Although the 2024 study definitively showed that purified RFT1 catalyzes translocation, the question of why earlier microsomal studies failed to detect RFT1-dependent activity remains incompletely understood. Identifying the confounding factors in those experiments could provide insights into the cellular organization of the N-glycosylation machinery.

7. Role in GPI anchor glycosylation: Studies in T. brucei suggest that RFT1 may influence GPI anchor side-chain modification in addition to N-glycosylation. Whether this broader role is conserved in humans, and whether GPI anchor defects contribute to RFT1-CDG pathology, remains to be investigated.

8. Dual localization significance: The observation that TbRFT1 localizes to both ER and Golgi raises questions about whether human RFT1 has similar dual localization and whether this reflects additional functions beyond LLO flipping in the ER.

References

1. [helenius-2002-rft1-nature-abstract] Helenius J, Ng DT, Marolda CL, Walter P, Valvano MA, Aebi M. Translocation of lipid-linked oligosaccharides across the ER membrane requires Rft1 protein. Nature. 2002 Jan 24;415(6870):447-50. PMID: 11807558. DOI: 10.1038/415447a. https://pubmed.ncbi.nlm.nih.gov/11807558/

2. [chen-2024-rft1-flippase-abstract] Chen S, Pei CX, Xu S, Li H, Liu YS, Wang Y, Jin C, Dean N, Gao XD. Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane. Nat Commun. 2024 Jun 17;15(1):5186. PMID: 38886340. PMCID: PMC11182771. DOI: 10.1038/s41467-024-48999-3. https://pubmed.ncbi.nlm.nih.gov/38886340/

3. [haeuptle-2008-rft1-cdg-abstract] Haeuptle MA, Pujol FM, Neupert C, Winchester B, Kastaniotis AJ, Aebi M, Hennet T. Human RFT1 deficiency leads to a disorder of N-linked glycosylation. Am J Hum Genet. 2008 Mar;82(3):600-6. PMID: 18313027. PMCID: PMC2427296. DOI: 10.1016/j.ajhg.2007.12.021. https://pubmed.ncbi.nlm.nih.gov/18313027/

4. [frank-2008-rft1-flip-abstract] Frank CG, Sanyal S, Rush JS, Waechter CJ, Menon AK. Does Rft1 flip an N-glycan lipid precursor? Nature. 2008 Aug 7;454(7205):732. PMID: 18668045. DOI: 10.1038/nature07165. https://pubmed.ncbi.nlm.nih.gov/18668045/

5. [rush-2009-rft1-microsomes-abstract] Rush JS, Gao N, Lehrman MA, Matveev S, Waechter CJ. Suppression of Rft1 expression does not impair the transbilayer movement of Man5GlcNAc2-P-P-dolichol in sealed microsomes from yeast. J Biol Chem. 2009 Jul 17;284(29):19835-42. PMID: 19494107. PMCID: PMC2740409. DOI: 10.1074/jbc.M109.000893. https://pubmed.ncbi.nlm.nih.gov/19494107/

6. [vleugels-2009-rft1-novel-cdg-abstract] Vleugels W, Haeuptle MA, Ng BG, Michalski JC, Battini R, Dionisi-Vici C, Ludman MD, Jaeken J, Foulquier F, Freeze HH, Matthijs G, Hennet T. RFT1 deficiency in three novel CDG patients. Hum Mutat. 2009 Oct;30(10):1428-34. PMID: 19701946. DOI: 10.1002/humu.21085. https://pubmed.ncbi.nlm.nih.gov/19701946/

7. [aeby-2016-rft1-epilepsy-abstract] Aeby A, Prigogine C, Vilain C, Malfilatre G, Jaeken J, Lederer D, Van Bogaert P. RFT1-congenital disorder of glycosylation (CDG) syndrome: a cause of early-onset severe epilepsy. Epileptic Disord. 2016 Mar;18(1):92-6. PMID: 26892341. DOI: 10.1684/epd.2016.0802. https://pubmed.ncbi.nlm.nih.gov/26892341/

8. [pei-2024-rft1-molecular-abstract] Pei CX, Bhattacharjee S, Bhattacharjee S, Dean N. Molecular characterization of Rft1, an ER membrane protein associated with congenital disorder of glycosylation RFT1-CDG. J Biol Chem. 2024 Aug;300(8):107583. PMID: 39025454. PMCID: PMC11014557. DOI: 10.1016/j.jbc.2024.107583. https://pubmed.ncbi.nlm.nih.gov/39025454/

9. [gottier-2017-rft1-gpi-abstract] Gottier P, Suter DM, Combes L, Zufferey M, Gönczy P, Bütikofer P. RFT1 Protein Affects Glycosylphosphatidylinositol (GPI) Anchor Glycosylation. J Biol Chem. 2017 Jan 20;292(3):853-864. PMID: 27927990. PMCID: PMC5247644. DOI: 10.1074/jbc.M116.758367. https://pubmed.ncbi.nlm.nih.gov/27927990/

10. [helenius-2004-nglycans-review-abstract] Helenius A, Aebi M. Roles of N-linked glycans in the endoplasmic reticulum. Annu Rev Biochem. 2004;73:1019-49. PMID: 15189166. DOI: 10.1146/annurev.biochem.73.011303.073752. https://pubmed.ncbi.nlm.nih.gov/15189166/

11. [human-protein-atlas] Human Protein Atlas. RFT1 Tissue Expression. https://www.proteinatlas.org/ENSG00000163933-RFT1/tissue

12. [omim-611908] OMIM Entry *611908 - RFT1 HOMOLOG; RFT1. https://omim.org/entry/611908

13. [sgd-rft1] Saccharomyces Genome Database. RFT1 / YBL020W. https://www.yeastgenome.org/locus/S000000116

Citations

1. aeby-2016-rft1-epilepsy-abstract.md
2. chen-2024-rft1-flippase-abstract.md
3. frank-2008-rft1-flip-abstract.md
4. gottier-2017-rft1-gpi-abstract.md
5. haeuptle-2008-rft1-cdg-abstract.md
6. helenius-2002-rft1-nature-abstract.md
7. helenius-2004-nglycans-review-abstract.md
8. pei-2024-rft1-molecular-abstract.md
9. rush-2009-rft1-microsomes-abstract.md
10. vleugels-2009-rft1-novel-cdg-abstract.md

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan
Objective 1. Verify identity and resolve ambiguities. Completed by cross-referencing 2024 mechanistic and molecular characterizations that explicitly study human RFT1 and its yeast/human orthology relationships, confirming the human ER protein RFT1 with polytopic topology, and by aligning mechanistic role and domains with RFT1/MOP family features (see Evidence). (hirata2024molecularcharacterizationof pages 1-3, hirata2024molecularcharacterizationof pages 8-10)
Objective 2–5. Curate primary literature, recent developments, disease relevance, and expert analysis; emphasize 2023–2024 sources. Achieved via 2024 Nature Communications (direct reconstitution) and 2024 molecular characterization, complemented by clinical/diagnostic primary literature and systematic reviews. (chen2024rft1catalyzeslipidlinked pages 2-3, chen2024rft1catalyzeslipidlinked pages 4-4, chen2024rft1catalyzeslipidlinked pages 5-6, hirata2024molecularcharacterizationof pages 1-3, vleugels2009rft1deficiencyin pages 1-3, colantuono2021liverinvolvementin pages 6-8, vleugels2009rft1deficiencyin pages 3-4)
Objective 6. Create a concise artifact table summarizing key facts. See embedded artifact.
Objective 7. Synthesize the full research report with citations and URLs. Submitted below.

Table: Concise, cited summary of key properties, function, evidence, disease links, diagnostics, and recent 2024 advances for human RFT1 (UniProt Q96AA3). This table compiles experimental and clinical sources to support functional annotation and translational relevance.

Comprehensive research report: Human RFT1 (UniProt Q96AA3)

1) Key concepts and definitions
• Identity and family: RFT1 (HGNC:30220) encodes a multi-pass ER membrane protein required for lipid-linked oligosaccharide (LLO) biogenesis in the N-glycosylation pathway. Recent structural homology and AlphaFold2 modeling place human RFT1 within the broader MOP (multidrug/oligosaccharidyl-lipid/polysaccharide) transporter superfamily that includes bacterial lipid II flippase MurJ, consistent with a transporter/scaffold for a large amphipathic lipid-linked glycan substrate (predicted ~14 TMs, cytosolic N- and C-termini). (Hirata et al., 2024; URL: https://doi.org/10.1101/2024.04.03.587922) (hirata2024molecularcharacterizationof pages 7-8, hirata2024molecularcharacterizationof pages 8-10)
• Primary substrate: the N-glycosylation intermediate Man5GlcNAc2-PP-dolichol (abbreviated M5GN2-PP-Dol or M5-DLO), which must move from the cytosolic to the luminal leaflet of the ER membrane to complete LLO assembly. (Chen et al., 2024; URL: https://doi.org/10.1038/s41467-024-48999-3) (chen2024rft1catalyzeslipidlinked pages 2-3)
• Pathway context: Synthesis of Glc3Man9GlcNAc2-PP-dolichol proceeds in two stages; the cytosolic heptasaccharide intermediate M5GN2-PP-Dol is flipped to the ER lumen where elongation yields Glc3Man9GlcNAc2-PP-Dol for transfer to nascent polypeptides by the OST complex. (Chen et al., 2024; URL: https://doi.org/10.1038/s41467-024-48999-3) (chen2024rft1catalyzeslipidlinked pages 2-3)

2) Molecular function, mechanism, localization, and topology
• Subcellular localization and topology: Human RFT1 localizes throughout the ER. DeepTMHMM and experimental tagging/topology mapping indicate ~14 transmembrane spans with both N- and C-termini facing the cytosol; the single canonical N-glycosylation sequon lies in an intracellular loop, and the protein is not N-glycosylated. (Hirata et al., 2024; URL: https://doi.org/10.1101/2024.04.03.587922) (hirata2024molecularcharacterizationof pages 7-8, hirata2024molecularcharacterizationof pages 22-26, hirata2024molecularcharacterizationof pages 8-10)
• Primary function and specificity: Purified human RFT1 directly catalyzes the transbilayer movement of M5GN2-PP-Dol (and the analogous phytanyl carrier substrate), with strong selectivity for M5 over shorter M3 intermediates in a fully reconstituted proteoliposome assay using an α-mannosidase/UPLC-MS readout. (Chen et al., 2024; URL: https://doi.org/10.1038/s41467-024-48999-3) (chen2024rft1catalyzeslipidlinked pages 4-4, chen2024rft1catalyzeslipidlinked pages 5-6)
• Mechanistic notes: Structural modeling predicts an inward-open, alternating-access–like transporter cavity containing conserved charged residues (e.g., R37, R63, R290, R442, E260) where many RFT1-CDG mutations map, consistent with a substrate-binding/translocation role for a large pyrophosphoryl-oligosaccharide lipid. (Hirata et al., 2024; URL: https://doi.org/10.1101/2024.04.03.587922) (hirata2024molecularcharacterizationof pages 8-10)

3) Recent developments and latest research (2023–2024)
• Definitive biochemical reconstitution: A major 2024 development resolved the long-standing controversy by demonstrating that purified Rft1 (yeast and human) is sufficient to catalyze M5GN2-PP-Dol translocation across membranes. Archaeal Agl23 also flips the same substrate, showing evolutionary conservation. These assays achieved ~90% conversion of M5GN2 to a diagnostic M3GN2 product accessible to exogenous mannosidase within 2 hours, while control liposomes or membrane fractions from an rft1Δ suppressor strain lacked activity. (Chen et al., 2024; URL: https://doi.org/10.1038/s41467-024-48999-3) (chen2024rft1catalyzeslipidlinked pages 4-4, chen2024rft1catalyzeslipidlinked pages 5-6)
• Molecular/structural characterization: Parallel 2024 work defined human RFT1 ER topology, quantified expression and glycosylation effects in yeast complementation, mapped conserved residues required for viability and N-glycosylation, and placed RFT1 in the MOP transporter superfamily. The same study reconciled prior biochemical observations where bulk M5-DLO scrambling persisted after Rft1 depletion by noting abundance differences and potential bypass/suppressor mechanisms; they emphasized the need for purified protein reconstitution (delivered by Chen et al. 2024). (Hirata et al., 2024; URL: https://doi.org/10.1101/2024.04.03.587922) (hirata2024molecularcharacterizationof pages 7-8, hirata2024molecularcharacterizationof pages 22-26, hirata2024molecularcharacterizationof pages 3-5)

4) Experimental evidence base
• Genetic complementation: Human RFT1 functionally replaces yeast Rft1 in viability and glycosylation assays; disease-residue variants define critical positions for function and growth. (Hirata et al., 2024; URL: https://doi.org/10.1101/2024.04.03.587922) (hirata2024molecularcharacterizationof pages 8-10)
• Biochemical reconstitution (purified protein): Direct flipping of M5GN2-PP-Dol/Phy by purified Rft1 in proteoliposomes with mannosidase-coupled UPLC-MS readout; selectivity for M5 over M3. (Chen et al., 2024; URL: https://doi.org/10.1038/s41467-024-48999-3) (chen2024rft1catalyzeslipidlinked pages 4-4, chen2024rft1catalyzeslipidlinked pages 5-6)
• Patient-cell functional rescue and LLO profiling: In RFT1-CDG fibroblasts, wild-type RFT1 cDNA corrects accumulated M5GN2-PP-Dol and restores secretion of a glycoprotein reporter (DNase I), establishing causality. (Vleugels et al., 2009; URL: https://doi.org/10.1002/humu.21085) (vleugels2009rft1deficiencyin pages 1-3, vleugels2009rft1deficiencyin pages 11-13)

5) Role in the N-glycosylation pathway
• Step: RFT1 flips the cytosolic M5GN2-PP-Dol intermediate into the ER lumen for elongation to Glc3Man9GlcNAc2-PP-Dol and downstream OST-mediated transfer to nascent polypeptides. (Chen et al., 2024; URL: https://doi.org/10.1038/s41467-024-48999-3) (chen2024rft1catalyzeslipidlinked pages 2-3)
• Pathway consequences of deficiency: Patient cells accumulate M5GN2-PP-Dol in the LLO pool with paucity of fully assembled LLO, leading to hypoglycosylation of proteins. (Vleugels et al., 2009; URL: https://doi.org/10.1002/humu.21085) (vleugels2009rft1deficiencyin pages 1-3, vleugels2009rft1deficiencyin pages 3-4)

6) Disease associations, phenotypes, and statistics
• Disorder: RFT1-CDG (OMIM 612015), an autosomal recessive congenital disorder of N-linked glycosylation. (Vleugels et al., 2009; URL: https://doi.org/10.1002/humu.21085) (vleugels2009rft1deficiencyin pages 6-7)
• Clinical spectrum (representative): severe neurodevelopmental disease (global developmental delay, hypotonia), intractable epilepsy including epileptic encephalopathy in infancy, universal sensorineural deafness in early series, feeding difficulties with aspiration, respiratory complications, and variable organ involvement (e.g., hepatomegaly reported; some series noted normal liver function). (Vleugels et al., 2009; URL: https://doi.org/10.1002/humu.21085; Colantuono et al., 2021; URL: https://doi.org/10.1097/mpg.0000000000003209) (vleugels2009rft1deficiencyin pages 4-6, vleugels2009rft1deficiencyin pages 6-7, colantuono2021liverinvolvementin pages 6-8)
• Reported case counts: Early clinical/molecular reports documented four total patients (three novel plus the index case). A later systematic review referenced “some of the nine patients reported” with RFT1-CDG features, indicating a total reported cohort on the order of single digits to low double digits in the literature at that time; overall, RFT1-CDG remains rare with few documented cases. (Vleugels et al., 2009; URL: https://doi.org/10.1002/humu.21085; Colantuono et al., 2021; URL: https://doi.org/10.1097/mpg.0000000000003209) (vleugels2009rft1deficiencyin pages 1-3, colantuono2021liverinvolvementin pages 6-8)

7) Diagnostics and real-world implementations
• Screening and confirmation: A Type I transferrin isoelectric focusing (IEF) pattern is typical of CDG-I defects. In RFT1-CDG, LLO profiling by radiolabel/HPLC demonstrates accumulation of M5GN2-PP-Dol with little fully assembled LLO and absence of M5GN2 on protein-linked glycans. Functional rescue by WT RFT1 in patient fibroblasts restores LLO composition and improves glycoprotein secretion (DNase I), supporting pathogenicity. These approaches inform clinical and research diagnostics. (Vleugels et al., 2009; URL: https://doi.org/10.1002/humu.21085) (vleugels2009rft1deficiencyin pages 3-4, vleugels2009rft1deficiencyin pages 11-13, vleugels2009rft1deficiencyin pages 1-3)
• Organ involvement in practice: Reviews emphasize neurological dominance, with reported hepatomegaly in some cases; phenotypes are heterogeneous, underscoring the utility of combined biochemical and genomic testing in suspected CDG. (Colantuono et al., 2021; URL: https://doi.org/10.1097/mpg.0000000000003209) (colantuono2021liverinvolvementin pages 6-8)

8) Expert analyses and interpretation
• Resolution of the “RFT1 flippase” controversy: 2024 purified-protein reconstitution provides direct biochemical evidence that Rft1 catalyzes M5GN2-PP-Dol flipping across membranes, reconciling earlier results where Rft1 depletion did not abolish bulk flipping in microsomes (likely due to suppressor/bypass and protein abundance issues). Structural/topological mapping supports a transporter mechanism aligned with MOP family principles and locates CDG mutations to a central cavity, strengthening the direct-actor model. (Chen et al., 2024; URL: https://doi.org/10.1038/s41467-024-48999-3; Hirata et al., 2024; URL: https://doi.org/10.1101/2024.04.03.587922) (chen2024rft1catalyzeslipidlinked pages 4-4, chen2024rft1catalyzeslipidlinked pages 5-6, hirata2024molecularcharacterizationof pages 7-8, hirata2024molecularcharacterizationof pages 8-10, hirata2024molecularcharacterizationof pages 22-26)
• Pathophysiology: Failure to flip M5GN2-PP-Dol impairs LLO completion, reducing N-glycosylation efficiency. The hallmark biochemical lesion—M5GN2-PP-Dol accumulation with paucity of mature LLO—correlates with hypoglycosylation-dependent clinical phenotypes in RFT1-CDG. (Vleugels et al., 2009; URL: https://doi.org/10.1002/humu.21085) (vleugels2009rft1deficiencyin pages 1-3, vleugels2009rft1deficiencyin pages 3-4)

9) Applications and implications
• Diagnostics: Incorporate RFT1 into gene panels for CDG; use transferrin IEF as an initial screen, followed by LLO profiling and functional complementation where feasible. (Vleugels et al., 2009; URL: https://doi.org/10.1002/humu.21085) (vleugels2009rft1deficiencyin pages 3-4, vleugels2009rft1deficiencyin pages 11-13)
• Biotechnology and basic science: The availability of purified active Rft1 enables mechanistic biochemistry on substrate recognition and transport, guiding design of reconstituted glycosylation systems and informing glycoengineering strategies that depend on LLO supply and quality. The evolutionary conservation (archaeal suppressor/ortholog activity) invites comparative studies of MOP transporters. (Chen et al., 2024; URL: https://doi.org/10.1038/s41467-024-48999-3) (chen2024rft1catalyzeslipidlinked pages 2-3, chen2024rft1catalyzeslipidlinked pages 5-6)

Mandatory verification summary
• Gene symbol/protein match: Studied protein is human RFT1, consistent with the UniProt Q96AA3 description and the literature (ER polytopic protein that mediates M5GN2-PP-Dol translocation). (Hirata et al., 2024; Chen et al., 2024) (hirata2024molecularcharacterizationof pages 1-3, chen2024rft1catalyzeslipidlinked pages 2-3)
• Organism: Homo sapiens; cross-species complementation confirms orthology with yeast Rft1; human RFT1 rescues yeast rft1 deficiency. (Hirata et al., 2024) (hirata2024molecularcharacterizationof pages 22-26)
• Family/domains: RFT1 shows predicted MOP superfamily features with a central hydrophilic cavity; many pathogenic variants map to conserved residues in this region. (Hirata et al., 2024) (hirata2024molecularcharacterizationof pages 8-10)
• Ambiguity check: No conflicting gene symbol usage impacting humans was identified in the curated sources; where earlier literature questioned direct flippase activity, 2024 purified-protein assays now support a direct catalytic role for RFT1. (Chen et al., 2024; Hirata et al., 2024) (chen2024rft1catalyzeslipidlinked pages 4-4, hirata2024molecularcharacterizationof pages 7-8)

References (URLs and dates)
• Chen S. et al. Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane. Nature Communications. 2024-06. URL: https://doi.org/10.1038/s41467-024-48999-3 (chen2024rft1catalyzeslipidlinked pages 2-3, chen2024rft1catalyzeslipidlinked pages 4-4, chen2024rft1catalyzeslipidlinked pages 5-6)
• Hirata E. et al. Molecular characterization of Rft1, an ER membrane protein associated with congenital disorder of glycosylation RFT1-CDG. 2024-04 (preprint/revised for JBC). URL: https://doi.org/10.1101/2024.04.03.587922 (hirata2024molecularcharacterizationof pages 1-3, hirata2024molecularcharacterizationof pages 7-8, hirata2024molecularcharacterizationof pages 22-26, hirata2024molecularcharacterizationof pages 8-10, hirata2024molecularcharacterizationof pages 40-41)
• Vleugels W. et al. RFT1 deficiency in three novel CDG patients. Human Mutation. 2009-10. URL: https://doi.org/10.1002/humu.21085 (vleugels2009rft1deficiencyin pages 1-3, vleugels2009rft1deficiencyin pages 4-6, vleugels2009rft1deficiencyin pages 6-7, vleugels2009rft1deficiencyin pages 11-13, vleugels2009rft1deficiencyin pages 3-4)
• Colantuono R. et al. Liver involvement in congenital disorders of glycosylation: a systematic review. JPGN. 2021-06. URL: https://doi.org/10.1097/mpg.0000000000003209 (colantuono2021liverinvolvementin pages 6-8)

References

1. (hirata2024molecularcharacterizationof pages 1-3): Eri Hirata, Ken-taro Sakata, Grace I. Dearden, Faria Noor, Indu Menon, George N. Chiduza, and Anant K. Menon. Molecular characterization of rft1, an er membrane protein associated with congenital disorder of glycosylation rft1-cdg. The Journal of Biological Chemistry, Apr 2024. URL: https://doi.org/10.1101/2024.04.03.587922, doi:10.1101/2024.04.03.587922. This article has 4 citations.

2. (hirata2024molecularcharacterizationof pages 8-10): Eri Hirata, Ken-taro Sakata, Grace I. Dearden, Faria Noor, Indu Menon, George N. Chiduza, and Anant K. Menon. Molecular characterization of rft1, an er membrane protein associated with congenital disorder of glycosylation rft1-cdg. The Journal of Biological Chemistry, Apr 2024. URL: https://doi.org/10.1101/2024.04.03.587922, doi:10.1101/2024.04.03.587922. This article has 4 citations.

3. (chen2024rft1catalyzeslipidlinked pages 2-3): Shuai Chen, Cai-Xia Pei, Si Xu, Hanjie Li, Yi-Shi liu, Yicheng Wang, Cheng Jin, Neta Dean, and Xiao-Dong Gao. Rft1 catalyzes lipid-linked oligosaccharide translocation across the er membrane. Nature Communications, Jun 2024. URL: https://doi.org/10.1038/s41467-024-48999-3, doi:10.1038/s41467-024-48999-3. This article has 15 citations and is from a highest quality peer-reviewed journal.

4. (chen2024rft1catalyzeslipidlinked pages 4-4): Shuai Chen, Cai-Xia Pei, Si Xu, Hanjie Li, Yi-Shi liu, Yicheng Wang, Cheng Jin, Neta Dean, and Xiao-Dong Gao. Rft1 catalyzes lipid-linked oligosaccharide translocation across the er membrane. Nature Communications, Jun 2024. URL: https://doi.org/10.1038/s41467-024-48999-3, doi:10.1038/s41467-024-48999-3. This article has 15 citations and is from a highest quality peer-reviewed journal.

5. (chen2024rft1catalyzeslipidlinked pages 5-6): Shuai Chen, Cai-Xia Pei, Si Xu, Hanjie Li, Yi-Shi liu, Yicheng Wang, Cheng Jin, Neta Dean, and Xiao-Dong Gao. Rft1 catalyzes lipid-linked oligosaccharide translocation across the er membrane. Nature Communications, Jun 2024. URL: https://doi.org/10.1038/s41467-024-48999-3, doi:10.1038/s41467-024-48999-3. This article has 15 citations and is from a highest quality peer-reviewed journal.

6. (vleugels2009rft1deficiencyin pages 1-3): Wendy Vleugels, Micha A. Haeuptle, Bobby G. Ng, Jean-Claude Michalski, Roberta Battini, Carlo Dionisi-Vici, Mark D. Ludman, Jaak Jaeken, François Foulquier, Hudson H. Freeze, Gert Matthijs, and Thierry Hennet. Rft1 deficiency in three novel cdg patients. Human Mutation, 30:1428-1434, Oct 2009. URL: https://doi.org/10.1002/humu.21085, doi:10.1002/humu.21085. This article has 44 citations and is from a domain leading peer-reviewed journal.

7. (colantuono2021liverinvolvementin pages 6-8): Rossella Colantuono, Elisa D’Acunto, Daniela Melis, Pietro Vajro, Hudson H. Freeze, and Claudia Mandato. Liver involvement in congenital disorders of glycosylation: a systematic review. Journal of Pediatric Gastroenterology and Nutrition, 73:444-454, Jun 2021. URL: https://doi.org/10.1097/mpg.0000000000003209, doi:10.1097/mpg.0000000000003209. This article has 12 citations and is from a peer-reviewed journal.

8. (vleugels2009rft1deficiencyin pages 3-4): Wendy Vleugels, Micha A. Haeuptle, Bobby G. Ng, Jean-Claude Michalski, Roberta Battini, Carlo Dionisi-Vici, Mark D. Ludman, Jaak Jaeken, François Foulquier, Hudson H. Freeze, Gert Matthijs, and Thierry Hennet. Rft1 deficiency in three novel cdg patients. Human Mutation, 30:1428-1434, Oct 2009. URL: https://doi.org/10.1002/humu.21085, doi:10.1002/humu.21085. This article has 44 citations and is from a domain leading peer-reviewed journal.

9. (hirata2024molecularcharacterizationof pages 22-26): Eri Hirata, Ken-taro Sakata, Grace I. Dearden, Faria Noor, Indu Menon, George N. Chiduza, and Anant K. Menon. Molecular characterization of rft1, an er membrane protein associated with congenital disorder of glycosylation rft1-cdg. The Journal of Biological Chemistry, Apr 2024. URL: https://doi.org/10.1101/2024.04.03.587922, doi:10.1101/2024.04.03.587922. This article has 4 citations.

10. (hirata2024molecularcharacterizationof pages 3-5): Eri Hirata, Ken-taro Sakata, Grace I. Dearden, Faria Noor, Indu Menon, George N. Chiduza, and Anant K. Menon. Molecular characterization of rft1, an er membrane protein associated with congenital disorder of glycosylation rft1-cdg. The Journal of Biological Chemistry, Apr 2024. URL: https://doi.org/10.1101/2024.04.03.587922, doi:10.1101/2024.04.03.587922. This article has 4 citations.

11. (hirata2024molecularcharacterizationof pages 7-8): Eri Hirata, Ken-taro Sakata, Grace I. Dearden, Faria Noor, Indu Menon, George N. Chiduza, and Anant K. Menon. Molecular characterization of rft1, an er membrane protein associated with congenital disorder of glycosylation rft1-cdg. The Journal of Biological Chemistry, Apr 2024. URL: https://doi.org/10.1101/2024.04.03.587922, doi:10.1101/2024.04.03.587922. This article has 4 citations.

12. (hirata2024molecularcharacterizationof pages 40-41): Eri Hirata, Ken-taro Sakata, Grace I. Dearden, Faria Noor, Indu Menon, George N. Chiduza, and Anant K. Menon. Molecular characterization of rft1, an er membrane protein associated with congenital disorder of glycosylation rft1-cdg. The Journal of Biological Chemistry, Apr 2024. URL: https://doi.org/10.1101/2024.04.03.587922, doi:10.1101/2024.04.03.587922. This article has 4 citations.

13. (vleugels2009rft1deficiencyin pages 11-13): Wendy Vleugels, Micha A. Haeuptle, Bobby G. Ng, Jean-Claude Michalski, Roberta Battini, Carlo Dionisi-Vici, Mark D. Ludman, Jaak Jaeken, François Foulquier, Hudson H. Freeze, Gert Matthijs, and Thierry Hennet. Rft1 deficiency in three novel cdg patients. Human Mutation, 30:1428-1434, Oct 2009. URL: https://doi.org/10.1002/humu.21085, doi:10.1002/humu.21085. This article has 44 citations and is from a domain leading peer-reviewed journal.

14. (vleugels2009rft1deficiencyin pages 6-7): Wendy Vleugels, Micha A. Haeuptle, Bobby G. Ng, Jean-Claude Michalski, Roberta Battini, Carlo Dionisi-Vici, Mark D. Ludman, Jaak Jaeken, François Foulquier, Hudson H. Freeze, Gert Matthijs, and Thierry Hennet. Rft1 deficiency in three novel cdg patients. Human Mutation, 30:1428-1434, Oct 2009. URL: https://doi.org/10.1002/humu.21085, doi:10.1002/humu.21085. This article has 44 citations and is from a domain leading peer-reviewed journal.

15. (vleugels2009rft1deficiencyin pages 4-6): Wendy Vleugels, Micha A. Haeuptle, Bobby G. Ng, Jean-Claude Michalski, Roberta Battini, Carlo Dionisi-Vici, Mark D. Ludman, Jaak Jaeken, François Foulquier, Hudson H. Freeze, Gert Matthijs, and Thierry Hennet. Rft1 deficiency in three novel cdg patients. Human Mutation, 30:1428-1434, Oct 2009. URL: https://doi.org/10.1002/humu.21085, doi:10.1002/humu.21085. This article has 44 citations and is from a domain leading peer-reviewed journal.

Citations

1. hirata2024molecularcharacterizationof pages 1-3
2. colantuono2021liverinvolvementin pages 6-8
3. hirata2024molecularcharacterizationof pages 40-41
4. hirata2024molecularcharacterizationof pages 8-10
5. hirata2024molecularcharacterizationof pages 22-26
6. hirata2024molecularcharacterizationof pages 3-5
7. hirata2024molecularcharacterizationof pages 7-8
8. https://doi.org/10.1038/s41467-024-48999-3
9. https://doi.org/10.1101/2024.04.03.587922
10. https://doi.org/10.1101/2024.04.03.587922;
11. https://doi.org/10.1002/humu.21085
12. https://doi.org/10.1097/mpg.0000000000003209
13. https://doi.org/10.1002/humu.21085;
14. https://doi.org/10.1038/s41467-024-48999-3;
15. https://doi.org/10.1101/2024.04.03.587922,
16. https://doi.org/10.1038/s41467-024-48999-3,
17. https://doi.org/10.1002/humu.21085,
18. https://doi.org/10.1097/mpg.0000000000003209,

RFT1: Key Flippase in N-Linked Glycosylation and Its Functional Annotation

Background: N-Linked Glycosylation and the Role of RFT1

N-linked glycosylation is a fundamental process in which a pre-assembled oligosaccharide is attached to specific asparagine residues of nascent proteins in the endoplasmic reticulum (ER) (pmc.ncbi.nlm.nih.gov). This oligosaccharide precursor – a 14-sugar Glc₃Man₉GlcNAc₂ structure in humans – is built on a lipid carrier (dolichol pyrophosphate) via a stepwise pathway (pmc.ncbi.nlm.nih.gov). The first seven sugars (two N-acetylglucosamines and five mannoses) are assembled on the cytosolic face of the ER, forming the intermediate Man₅GlcNAc₂-PP-dolichol (also called M5-DLO or a “heptasaccharide” lipid intermediate) (pmc.ncbi.nlm.nih.gov). This intermediate must then be flipped or translocated across the ER membrane into the lumen, where the remaining seven sugars (four mannoses and three glucoses) are added to complete the precursor (pmc.ncbi.nlm.nih.gov). The protein RFT1 – identified in yeast around 2002 as “Required for Flipping of Man₅GlcNAc₂-PP-dolichol” – is the membrane transporter responsible for this translocation step (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In other words, RFT1 functions as the ER flippase (or scramblase) that flips the lipid-linked oligosaccharide from the cytosolic leaflet to the luminal leaflet of the ER membrane, a step essential for N-glycan biosynthesis (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This role is critical: without RFT1, the oligosaccharide cannot reach the lumen and be matured or transferred to proteins, stalling the entire N-glycosylation pathway (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Key Concept – Lipid-Linked Oligosaccharide Flipping: RFT1 specifically translocates the Man₅GlcNAc₂-PP-dolichol intermediate across the ER membrane. Genetic studies first implicated RFT1 in this process (Helenius et al., 2002) when yeast lacking Rft1 accumulated the intermediate and failed to complete glycosylation (pmc.ncbi.nlm.nih.gov). Correspondingly, when the human RFT1 gene is nonfunctional, cells also accumulate Man₅GlcNAc_{2>-PP-dolichol on the cytosolic side, underscoring that the flipping step is blocked (pmc.ncbi.nlm.nih.gov). Biochemically, this flipping is ATP-independent – RFT1 acts as a lipid scramblase that facilitates the equilibrative movement of the glycolipid between membrane leaflets (pmc.ncbi.nlm.nih.gov). It exhibits high specificity for the dolichol-linked heptasaccharide, ensuring that this exact precursor (and not unrelated lipids) is efficiently translocated (pmc.ncbi.nlm.nih.gov). After flipping by RFT1, the complete Glc3Man9GlcNAc2 glycan is assembled in the lumen and then transferred en bloc to proteins by oligosaccharyltransferase (OST) (pmc.ncbi.nlm.nih.gov). Thus, RFT1’s primary function is to enable the key translocation step that connects cytosolic and luminal phases of N-glycan assembly, a role conserved across eukaryotic life (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).}

Molecular Characteristics and Localization of RFT1

Human RFT1 (UniProt Q96AA3) is an ER-resident multi-pass membrane protein consisting of 541 amino acids. Both its N-terminus and C-terminus face the cytosolic side of the ER membrane (pmc.ncbi.nlm.nih.gov). Topology studies and predictive modeling indicate that RFT1 spans the membrane ~14 times, forming a complex transmembrane structure (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Notably, RFT1 has no confirmed glycosylation sites of its own (it is not N-glycosylated), consistent with an orientation where any luminal loops are short or inaccessible for glycan attachment (pmc.ncbi.nlm.nih.gov). The protein belongs to the RFT1 family (Pfam PF04506), an evolutionarily conserved family of ER proteins found in virtually all eukaryotes (from yeast to humans) (pmc.ncbi.nlm.nih.gov). Despite low sequence identity between distant orthologs – for example, human RFT1 shares only ~22% amino-acid identity with yeast Rft1 – these proteins are functionally interchangeable, indicating strong conservation at the functional level (pmc.ncbi.nlm.nih.gov). Experiments have shown that human RFT1 can complement an RFT1 deletion in yeast, restoring normal growth and glycosylation, whereas a disease-mutant form of human RFT1 cannot (pmc.ncbi.nlm.nih.gov). This cross-species complementation underscores that the core function of RFT1 has been preserved even if the primary sequences diverged significantly (pmc.ncbi.nlm.nih.gov).

At the structural level, recent analyses suggest that RFT1 adopts a fold reminiscent of the MOP superfamily of transporters (the Multidrug/Oligosaccharidyl-lipid/Polysaccharide flippase family) (pmc.ncbi.nlm.nih.gov). In fact, computational models (AlphaFold2, 2024) indicate RFT1’s transmembrane domain is organized into two symmetric halves (each ~7 TM helices) forming a hydrophilic central cavity (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This architecture is strikingly similar to known lipid flippases such as bacterial MurJ, which uses an alternating-access mechanism to flip lipid-linked peptidoglycan precursors (pmc.ncbi.nlm.nih.gov). The RFT1 model appears in an inward-open conformation, with a water-exposed cavity facing the cytosol that likely accommodates the Man₅GlcNAc₂-PP-dolichol substrate (pmc.ncbi.nlm.nih.gov). Key conserved residues line this cavity and are thought to mediate substrate binding and translocation (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Notably, most missense mutations identified in patients with RFT1 deficiency cluster in these conserved regions of the protein, highlighting their importance for function (pmc.ncbi.nlm.nih.gov). Together, these structural features support a model in which RFT1 “grabs” the heptasaccharide-pyrophosphate dolichol on the cytosolic side and swivels to release it on the luminal side – a classic alternating-access transport mechanism analogous to other known lipid flippases (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Consistent with this idea, purified RFT1 protein reconstituted into liposomes is sufficient to mediate flipping without any other ER factors, suggesting RFT1 alone forms the active translocation pore or channel for the lipid-linked oligosaccharide (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Cellular Localization: RFT1 is an integral membrane protein of the endoplasmic reticulum. Endogenous RFT1 localizes to the ER membrane where N-glycan assembly occurs (pmc.ncbi.nlm.nih.gov). It is not found in the plasma membrane or other organelles, as its function is tightly linked to the ER’s dolichol pathway. In mammalian cells, RFT1’s expression is essential for viability – cells lacking RFT1 cannot survive due to failure of protein glycosylation (pmc.ncbi.nlm.nih.gov). Similarly, yeast RFT1 is an essential gene under normal conditions (pmc.ncbi.nlm.nih.gov). (One notable exception is Trypanosoma brucei, a parasitic protozoan where RFT1 is surprisingly non-essential for growth (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This organism appears to have an alternate mechanism or bypass for LLO flipping, as discussed below.) Overall, RFT1 predominantly resides in ER membranes and carries out its transporter function co-translationally as the LLO is synthesized, ensuring that glycan assembly can seamlessly continue on the luminal side.

Functional Evidence and Mechanism: Flipping the Lipid-Linked Oligosaccharide

Biochemical and genetic evidence strongly indicate that RFT1’s primary substrate is the lipid-linked heptasaccharide Man₅GlcNAc₂-PP-dolichol. In a landmark human study (Haeuptle et al., 2008), a young patient was found to accumulate this exact intermediate in cells due to a defective RFT1 gene (pmc.ncbi.nlm.nih.gov). The accumulation of Man₅GlcNAc₂-PP-dolichol on the cytosolic side (with a corresponding shortage of fully assembled Glc₃Man₉GlcNAc₂ in the lumen) is a clear biochemical signature of a flipping blockade (pmc.ncbi.nlm.nih.gov). Restoring a functional RFT1 in these patient cells allowed the intermediate to be properly utilized and normal glycosylation to resume (pmc.ncbi.nlm.nih.gov). This finding mirrors earlier yeast genetic studies (Helenius et al., 2002) in which rft1 mutants accumulated the same heptasaccharide and could not complete N-glycosylation (pmc.ncbi.nlm.nih.gov). Together, these results established that RFT1 is required for translocating Man₅GlcNAc₂-PP-dolichol from the cytoplasmic to luminal ER leaflet**, a step that is indispensable for assembling the complete N-glycan precursor (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Without RFT1, the downstream ER-localized glycosyltransferases (Alg3, Alg9, Alg12 for mannose and Alg6/8/10 for glucose additions) cannot access the substrate, leading to under-glycosylated proteins and severe cellular dysfunction (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Mechanistically, RFT1 appears to function as a selective scramblase. It does not hydrolyze ATP or use any obvious energy source; instead, it facilitates the flip-flop of the pyrophosphate-linked oligosaccharide down its concentration gradient in a highly selective manner (pmc.ncbi.nlm.nih.gov). Early studies suggested the existence of an ATP-independent flippase activity in ER membranes specific for the LLO intermediate (pmc.ncbi.nlm.nih.gov). RFT1 fits this profile: it likely lowers the energy barrier for the charged, bulky Man₅GlcNAc₂-PP-dolichol to traverse the hydrophobic membrane. Importantly, this specificity distinguishes RFT1 from general lipid scramblases that indiscriminately equilibrate lipids. In vitro assays have confirmed that RFT1 does not flip simpler lipid phosphates (like phosphatidylcholine) but does translocate the dolichol-linked oligosaccharide (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This agrees with the idea that RFT1’s transmembrane cavity is tailored to recognize the polyprenol-pyrophosphate glycan headgroup. Intriguingly, some evidence suggests RFT1 might also assist in flipping other lipid-linked glycans. For example, a study in T. brucei (Gottier et al., 2017) found that loss of RFT1 affected GPI anchor glycosylation, implying RFT1 may partake in translocation of the glycolipid intermediates of GPI anchor biosynthesis as well (pmc.ncbi.nlm.nih.gov). While human RFT1’s involvement in GPI precursor flipping remains less clear, this observation raises the possibility that RFT1’s “substrate” could include multiple glycolipid types in organisms that lack alternative flippases. Nonetheless, the best-established and primary role of RFT1 in human cells is the flipping of the N-glycan lipid precursor Man₅GlcNAc₂-PP-Dol, a prerequisite for proper N-linked protein glycosylation (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Historical Controversy and Recent Advances (2023–2024)

For over two decades, the identity of the ER LLO flippase was a subject of debate (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Initial genetic evidence in yeast (2002) and the first human case (2008) strongly pointed to RFT1 as the required flippase, since RFT1 loss caused the expected glycosylation defect in vivo (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). However, subsequent biochemical studies in 2008–2009 challenged this interpretation. In 2008, Menon and colleagues reconstituted ER membrane vesicles and reported that Man₅GlcNAc₂-PP-Dol flipping occurred even in the apparent absence of RFT1, suggesting “a specific ER protein(s), but not Rft1, is required to flip” the LLO precursor (www.nature.com). Similarly, a 2009 study by Rush et al. found that yeast microsomes with greatly reduced Rft1 still showed normal translocation of the heptasaccharide, implying redundant or RFT1-independent flipping activity (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). These findings led to a hypothesis that RFT1 might play an indirect or accessory role (perhaps as a chaperone for the LLO or in maintaining membrane homeostasis) rather than being the flippase itself (www.nature.com). The mystery deepened when Jelk et al. (2013) discovered that Trypanosoma brucei can survive without any RFT1, yet still glycosylate its proteins – evidence that an alternate flippase exists in that organism (pmc.ncbi.nlm.nih.gov). By the mid-2010s, RFT1 was the only protein ever implicated in LLO translocation, but definitive proof of its direct role was lacking and many experts remained skeptical of its function (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Reviews of congenital glycosylation disorders even highlighted the “enigmatic” nature of RFT1, noting that its essential role in most eukaryotes was clear despite the contradictory in vitro data (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Resolution – Direct Flippase Proof: The long-standing controversy was resolved by new research in 2023–2024. In June 2024, a breakthrough study in Nature Communications by Shuai Chen et al. provided unequivocal evidence that RFT1 itself catalyzes lipid-linked oligosaccharide flipping (pmc.ncbi.nlm.nih.gov). The researchers purified RFT1 (from yeast and human) and reconstituted it into artificial liposomes, then monitored transport of a fluorescently labeled Man₅GlcNAc₂-PP-dolichol analog. They demonstrated that RFT1 alone is sufficient to translocate the oligosaccharide across the bilayer in vitro (pmc.ncbi.nlm.nih.gov). This work showed substrate specificity matching the in vivo requirements – RFT1 robustly flipped the full pyrophosphate-linked heptasaccharide, whereas simpler dolichol-phosphate sugars were not transported (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In the same assays, an unrelated control protein could not substitute for RFT1, confirming the activity was intrinsic to RFT1. Notably, the Nature Communications study also tested an archaeal protein (Haloarcula Agl23) that had been discovered via a genetic suppressor screen: remarkably, Agl23 – which has no sequence homology to RFT1 – could flip the LLO intermediate just like RFT1 (pmc.ncbi.nlm.nih.gov). Agl23 had been found capable of rescuing yeast lacking RFT1, and in the reconstituted system it, too, catalyzed efficient flipping of Man₅GlcNAc₂-PP-dolichol (or a polyprenol analog) (pmc.ncbi.nlm.nih.gov). This provided independent validation that flipping can be accomplished by at least two structurally distinct proteins, underscoring that it is flippase activity per se that is critical, whether provided by RFT1 or a surrogate (pmc.ncbi.nlm.nih.gov). Together, these results “unequivocally support the idea that Rft1, from both yeast and human, is directly responsible” for translocating the LLO intermediate in eukaryotic cells (pmc.ncbi.nlm.nih.gov).

Concurrently, other researchers have solidified our understanding of RFT1’s structure-function. In July 2024, a study in Journal of Biological Chemistry (Hirata et al., 2024) provided a detailed molecular characterization of human RFT1 using yeast as a model system (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This work confirmed that RFT1 is a multi-spanning ER protein with no glycosylation, and identified several critical residues required for its function by testing mutant variants in yeast (pmc.ncbi.nlm.nih.gov). The JBC study’s structural analysis reinforced the similarity between RFT1 and bacterial flippases like MurJ, lending a strong theoretical framework for how RFT1 works (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). With modern tools, the authors could finally reconcile the old discrepancies: they suggested that earlier in vitro assays likely had unidentified ER scramblases keeping partial flipping activity in RFT1-depleted preparations, whereas the 2024 reconstitution used highly purified components to attribute activity specifically to RFT1 (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In summary, as of 2024, consensus has been reached that RFT1 is the bona fide ER flippase for the N-glycan precursor, resolving a decades-long question in cell biology (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This resolution fills an important gap in the canonical N-glycosylation pathway and is hailed as a significant advance in our understanding of membrane transport mechanisms in glycoprotein biosynthesis (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Clinical Significance: RFT1-Congenital Disorder of Glycosylation (CDG-In)

RFT1 deficiency in humans causes a severe congenital disorder of glycosylation, underscoring the protein’s indispensable role in vivo (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The first patient with RFT1-CDG was reported in 2008 (an infant with a homozygous RFT1 missense mutation, p.R67C) and presented with a profound multisystem disease (pmc.ncbi.nlm.nih.gov). Biochemical analysis of this patient’s cells revealed an intracellular build-up of Man₅GlcNAc₂-PP-dolichol and abnormally under-glycosylated serum glycoproteins, directly linking the RFT1 mutation to a defect in N-linked glycan assembly (pmc.ncbi.nlm.nih.gov). Expression of normal RFT1 cDNA in the patient’s fibroblasts rescued the glycosylation defect, proving causality of the RFT1 mutation (pmc.ncbi.nlm.nih.gov). Following this discovery, a handful of additional cases were identified worldwide (three new cases were described by 2009), and the disorder has been designated “RFT1-CDG” or CDG type In (CDG-In, in the original nomenclature) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). RFT1-CDG is inherited in an autosomal recessive manner and is extremely rare – only a few families have been documented in the literature (pmc.ncbi.nlm.nih.gov).

Clinically, RFT1-CDG patients exhibit the hallmark features of many N-glycosylation disorders, combined with some distinctive symptoms. Infants typically show failure to thrive, hypotonia (low muscle tone), and developmental delays from early on (pmc.ncbi.nlm.nih.gov). Neurological problems are prominent, including seizures or myoclonic jerks and intellectual disability (pmc.ncbi.nlm.nih.gov). Organ systems such as the liver and gut can be affected, and dysmorphic features or skeletal abnormalities are sometimes noted, reflecting the systemic importance of glycoproteins (pmc.ncbi.nlm.nih.gov). Strikingly, sensorineural deafness has been observed in all reported RFT1-CDG patients – an unusual feature not seen in most other CDG subtypes (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This consistent deafness, alongside the severe neurodevelopmental impairment, suggests that certain cell types (e.g. inner ear neurons and brain cells) are especially sensitive to defects in the LLO flipping step (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Indeed, researchers have noted that RFT1-CDG is “mainly a neurological disorder,” with the ear pathology as a notable clue (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). There is currently no cure for RFT1-CDG; management is supportive and focuses on treating symptoms (for example, anti-seizure medications and nutritional support). Early death in childhood is common in the severe cases reported (pmc.ncbi.nlm.nih.gov). The identification of RFT1-CDG has, however, enabled genetic diagnosis for affected families. RFT1 gene sequencing is now included in CDG diagnostic panels (listed as CDG-1N in genetic testing registries) (www.ncbi.nlm.nih.gov). This allows for carrier testing and prenatal diagnosis, which are important given the recessive inheritance and high medical burden of the disease. RFT1-CDG is one of more than 30 known genetic defects in the N-linked glycosylation pathway (pmc.ncbi.nlm.nih.gov), and each such discovery (RFT1 included) has provided valuable insight into human glycan biosynthesis. In particular, RFT1-CDG cases offered in vivo confirmation that the Man₅GlcNAc₂-PP-Dol flippase step is critically important for human development (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Current Applications and Future Directions

The elucidation of RFT1’s function has several important applications in biomedicine and biotechnology. Diagnostic Medicine: As described above, knowing the molecular basis of RFT1-CDG allows clinicians to diagnose this disorder via genetic testing and abnormal glycosylation screening (e.g. transferrin isoform analysis) (pmc.ncbi.nlm.nih.gov). For families affected by RFT1-CDG, genetic counseling and early intervention become possible now that the gene is identified. Moreover, RFT1-CDG stands as a model for developing therapies for glycosylation disorders. One experimental approach demonstrated in 2008 was to use a lentiviral vector expressing wild-type RFT1 to “cure” patient cells in culture (pmc.ncbi.nlm.nih.gov). This gene therapy concept – replacing the defective flippase gene – successfully restored normal glycan profiles in vitro (pmc.ncbi.nlm.nih.gov). While actual gene therapy in patients would face significant hurdles, this result provides a proof-of-principle that correcting the flip defect can rescue cell function. As gene delivery techniques improve, RFT1 might be considered a candidate for future gene therapy trials in CDG (especially if a patient presents with a milder, partially active mutation that could be complemented). Additionally, understanding RFT1’s activity enables screening for small molecules or pharmacological chaperones that might stabilize certain mutant RFT1 proteins. If a partial loss-of-function mutant is misfolded, a drug that improves its folding could restore some flipping activity – a strategy being explored for other protein-misfolding CDGs (pmc.ncbi.nlm.nih.gov).

Research and Biotechnology: The definitive identification of RFT1 as the LLO flippase also has practical implications for research and bioengineering. In glycobiology research, the availability of an in vitro flipping assay (thanks to purified RFT1 reconstitution) is a significant advancement (pmc.ncbi.nlm.nih.gov). This assay can be used to interrogate the mechanism of translocation in detail – for instance, to determine how fast RFT1 flips the lipid, whether any ion gradients or membrane conditions modulate its activity, and whether accessory proteins influence efficiency. It also opens the door to high-resolution structural studies (e.g. cryo-EM efforts) now that a functional preparation of RFT1 is in hand. Early modeling suggests RFT1 operates via an alternating-access mechanism (pmc.ncbi.nlm.nih.gov), and future studies may capture different conformational states of RFT1 or even co-complexes with the LLO substrate. Such structural insights could be invaluable for rational drug design if one ever aims to modulate N-glycosylation (for example, tweaking glycan profiles in biotech production of therapeutic glycoproteins). In biotechnology, engineering robust N-glycosylation pathways in non-native systems (like yeast or microalgae used to produce recombinant proteins) requires a functional flippase. The confirmation that RFT1 is the required flippase means that any glyco-engineering effort must ensure RFT1 (or an equivalent activity) is present. Indeed, the discovery that an archaeal protein (Agl23) can substitute for RFT1’s function (pmc.ncbi.nlm.nih.gov) hints that there may be bioengineered solutions to bypass defects or optimize glycosylation. For instance, if a particular production strain has low endogenous flipping efficiency, introducing a more efficient flippase (perhaps a variant or a surrogate from another species) might enhance glycoprotein yield or fidelity.

Finally, RFT1’s study has broader significance in cell biology. It exemplifies how cells handle hydrophilic substrates within membranes and has stimulated comparisons to other lipid transport processes. The knowledge gained from RFT1 is informing research on analogous systems, such as flippases for GPI anchors and other glycolipids. As noted, RFT1 may not act entirely alone in living cells – there could be a network of membrane proteins ensuring all kinds of lipid-linked sugars are properly oriented. By studying RFT1, scientists are also learning how membrane topology and protein machinery co-evolved to manage complex lipid-linked reactions. In summary, the current understanding of RFT1 – solidified by recent research – not only completes the puzzle of the N-linked glycosylation pathway but also provides a foundation for medical and biotechnological advances. This ER transporter, once controversial, is now recognized as a crucial enzyme-like protein that bridges two phases of glycan assembly, with real-world impacts from diagnosing rare diseases to potentially improving biomanufacturing of glycoproteins. The ongoing research and expert analyses uniformly highlight RFT1 as “the” Man₅GlcNAc₂-PP-Dol flippase in eukaryotes (pmc.ncbi.nlm.nih.gov), reflecting a consensus built on decades of study and culminating in the latest findings of 2024.

References: Recent authoritative sources supporting this report include Nature Communications (June 17, 2024) which provided direct biochemical evidence for RFT1’s flippase activity (pmc.ncbi.nlm.nih.gov), and J. Biol. Chem. (July 2024) which detailed RFT1’s structure-function characteristics (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Foundational studies in Nature (Helenius et al., 2002) first implicated RFT1 in LLO translocation (pmc.ncbi.nlm.nih.gov), while an Am. J. Hum. Genet. paper (Feb 2008) identified RFT1 mutations in CDG patients (pmc.ncbi.nlm.nih.gov). The back-and-forth debate in the literature (e.g. Frank et al., Nature 2008 (www.nature.com), and subsequent discussions) has now been put to rest by the convergence of genetic, clinical, and biochemical data. These sources, along with others cited throughout this report, provide a comprehensive, up-to-date view of RFT1’s function, importance, and emerging applications.

Citations

1. AnnotationURLCitation(end_index=464, start_index=326, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=Asparagine%20%28N%29,P%2C%20GlcNAc%20and%20five%20Man')
2. AnnotationURLCitation(end_index=799, start_index=659, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=Glc3Man9GlcNAc2%20,to%20the%20asparagine%20residue%20of')
3. AnnotationURLCitation(end_index=1200, start_index=1054, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=topologically%20distinct,to%20the%20asparagine%20residue%20of')
4. AnnotationURLCitation(end_index=1548, start_index=1402, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=topologically%20distinct,to%20the%20asparagine%20residue%20of')
5. AnnotationURLCitation(end_index=1926, start_index=1749, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=identified%20Rft1%20by%20yeast%20genetics,vitro%20flipping%20assay%20using%20proteoliposomes')
6. AnnotationURLCitation(end_index=2073, start_index=1927, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=topologically%20distinct,to%20the%20asparagine%20residue%20of')
7. AnnotationURLCitation(end_index=2456, start_index=2300, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=translocation%20and%20demonstrate%20that%20purified,Dol%20ER%20flippase')
8. AnnotationURLCitation(end_index=2603, start_index=2457, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=topologically%20distinct,to%20the%20asparagine%20residue%20of')
9. AnnotationURLCitation(end_index=2886, start_index=2772, title='Human RFT1 Deficiency Leads to a Disorder of N-Linked Glycosylation - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2427296/#:~:text=N,The%20human%20RFT1%20protein')
10. AnnotationURLCitation(end_index=3033, start_index=2887, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=topologically%20distinct,to%20the%20asparagine%20residue%20of')
11. AnnotationURLCitation(end_index=3555, start_index=3378, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=identified%20Rft1%20by%20yeast%20genetics,vitro%20flipping%20assay%20using%20proteoliposomes')
12. AnnotationURLCitation(end_index=3864, start_index=3750, title='Human RFT1 Deficiency Leads to a Disorder of N-Linked Glycosylation - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2427296/#:~:text=N,The%20human%20RFT1%20protein')
13. AnnotationURLCitation(end_index=4205, start_index=4040, title='Molecular characterization of Rft1, an ER membrane protein associated with congenital disorder of glycosylation RFT1-CDG - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11365447/#:~:text=the%20necessary%20glycosyltransferases%20are%20known%2C,glycosylation%20underlie')
14. AnnotationURLCitation(end_index=4532, start_index=4367, title='Molecular characterization of Rft1, an ER membrane protein associated with congenital disorder of glycosylation RFT1-CDG - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11365447/#:~:text=the%20necessary%20glycosyltransferases%20are%20known%2C,glycosylation%20underlie')
15. AnnotationURLCitation(end_index=4875, start_index=4729, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=topologically%20distinct,to%20the%20asparagine%20residue%20of')
16. AnnotationURLCitation(end_index=5229, start_index=5052, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=identified%20Rft1%20by%20yeast%20genetics,vitro%20flipping%20assay%20using%20proteoliposomes')
17. AnnotationURLCitation(end_index=5386, start_index=5230, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=translocation%20and%20demonstrate%20that%20purified,Dol%20ER%20flippase')
18. AnnotationURLCitation(end_index=5788, start_index=5628, title='Molecular characterization of Rft1, an ER membrane protein associated with congenital disorder of glycosylation RFT1-CDG - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11365447/#:~:text=Rft1%2C%20using%20yeast%20cells%20as,work%20on%20this%20enigmatic%20protein')
19. AnnotationURLCitation(end_index=6065, start_index=5922, title='Molecular characterization of Rft1, an ER membrane protein associated with congenital disorder of glycosylation RFT1-CDG - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11014557/#:~:text=Structure%20prediction%20by%20AlphaFold2%20,Scores%20range')
20. AnnotationURLCitation(end_index=6175, start_index=6066, title='Molecular characterization of Rft1, an ER membrane protein associated with congenital disorder of glycosylation RFT1-CDG - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11014557/#:~:text=F,7%20of%20the%2014%20TM')
21. AnnotationURLCitation(end_index=6532, start_index=6372, title='Molecular characterization of Rft1, an ER membrane protein associated with congenital disorder of glycosylation RFT1-CDG - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11365447/#:~:text=Rft1%2C%20using%20yeast%20cells%20as,work%20on%20this%20enigmatic%20protein')
22. AnnotationURLCitation(end_index=6877, start_index=6700, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=identified%20Rft1%20by%20yeast%20genetics,vitro%20flipping%20assay%20using%20proteoliposomes')
23. AnnotationURLCitation(end_index=7244, start_index=7120, title='Human RFT1 Deficiency Leads to a Disorder of N-Linked Glycosylation - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2427296/#:~:text=found%20to%20carry%20a%20homozygous,R67C')
24. AnnotationURLCitation(end_index=7593, start_index=7421, title='Human RFT1 Deficiency Leads to a Disorder of N-Linked Glycosylation - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2427296/#:~:text=found%20to%20carry%20a%20homozygous,restoration%20of%20normal%20glycosylation%20profiles')
25. AnnotationURLCitation(end_index=7921, start_index=7749, title='Human RFT1 Deficiency Leads to a Disorder of N-Linked Glycosylation - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2427296/#:~:text=found%20to%20carry%20a%20homozygous,restoration%20of%20normal%20glycosylation%20profiles')
26. AnnotationURLCitation(end_index=8282, start_index=8122, title='Molecular characterization of Rft1, an ER membrane protein associated with congenital disorder of glycosylation RFT1-CDG - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11014557/#:~:text=Both%20the%20AlphaFold2%20model%20and,MurJ%20lipid%20II%20flippases%20which')
27. AnnotationURLCitation(end_index=8576, start_index=8467, title='Molecular characterization of Rft1, an ER membrane protein associated with congenital disorder of glycosylation RFT1-CDG - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11014557/#:~:text=F,7%20of%20the%2014%20TM')
28. AnnotationURLCitation(end_index=8716, start_index=8577, title='Molecular characterization of Rft1, an ER membrane protein associated with congenital disorder of glycosylation RFT1-CDG - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11014557/#:~:text=match%20at%20L595%20potenqal%20%2858%E2%80%9361%29,Fig')
29. AnnotationURLCitation(end_index=9056, start_index=8896, title='Molecular characterization of Rft1, an ER membrane protein associated with congenital disorder of glycosylation RFT1-CDG - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11014557/#:~:text=Both%20the%20AlphaFold2%20model%20and,MurJ%20lipid%20II%20flippases%20which')
30. AnnotationURLCitation(end_index=9384, start_index=9245, title='Molecular characterization of Rft1, an ER membrane protein associated with congenital disorder of glycosylation RFT1-CDG - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11014557/#:~:text=match%20at%20L595%20potenqal%20%2858%E2%80%9361%29,Fig')
31. AnnotationURLCitation(end_index=9649, start_index=9489, title='Molecular characterization of Rft1, an ER membrane protein associated with congenital disorder of glycosylation RFT1-CDG - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11014557/#:~:text=Both%20the%20AlphaFold2%20model%20and,MurJ%20lipid%20II%20flippases%20which')
32. AnnotationURLCitation(end_index=9788, start_index=9650, title='Molecular characterization of Rft1, an ER membrane protein associated with congenital disorder of glycosylation RFT1-CDG - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11014557/#:~:text=plays%20in%20N,work%20on%20this%20enigmatic%20protein')
33. AnnotationURLCitation(end_index=10099, start_index=9961, title='Molecular characterization of Rft1, an ER membrane protein associated with congenital disorder of glycosylation RFT1-CDG - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11014557/#:~:text=plays%20in%20N,work%20on%20this%20enigmatic%20protein')
34. AnnotationURLCitation(end_index=10538, start_index=10378, title='Molecular characterization of Rft1, an ER membrane protein associated with congenital disorder of glycosylation RFT1-CDG - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11014557/#:~:text=Both%20the%20AlphaFold2%20model%20and,MurJ%20lipid%20II%20flippases%20which')
35. AnnotationURLCitation(end_index=10678, start_index=10539, title='Molecular characterization of Rft1, an ER membrane protein associated with congenital disorder of glycosylation RFT1-CDG - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11014557/#:~:text=match%20at%20L595%20potenqal%20%2858%E2%80%9361%29,Fig')
36. AnnotationURLCitation(end_index=11043, start_index=10928, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=complex,independent%20flippase')
37. AnnotationURLCitation(end_index=11218, start_index=11044, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=our%20results%20unequivocally%20support%20the,ER%20membrane%20during%20LLO%20biosynthesis')
38. AnnotationURLCitation(end_index=11552, start_index=11392, title='Molecular characterization of Rft1, an ER membrane protein associated with congenital disorder of glycosylation RFT1-CDG - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11365447/#:~:text=Rft1%2C%20using%20yeast%20cells%20as,work%20on%20this%20enigmatic%20protein')
39. AnnotationURLCitation(end_index=11966, start_index=11819, title='Molecular characterization of Rft1, an ER membrane protein associated with congenital disorder of glycosylation RFT1-CDG - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11365447/#:~:text=including%20RFT1,a%20molecular%20characterization%20of%20human')
40. AnnotationURLCitation(end_index=12214, start_index=12037, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=identified%20Rft1%20by%20yeast%20genetics,vitro%20flipping%20assay%20using%20proteoliposomes')
41. AnnotationURLCitation(end_index=12495, start_index=12338, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=match%20at%20L104%20yeast%20cells%2C,date%2C%20the%20identity%20of%20the')
42. AnnotationURLCitation(end_index=12643, start_index=12496, title='Molecular characterization of Rft1, an ER membrane protein associated with congenital disorder of glycosylation RFT1-CDG - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11365447/#:~:text=including%20RFT1,a%20molecular%20characterization%20of%20human')
43. AnnotationURLCitation(end_index=13487, start_index=13373, title='Human RFT1 Deficiency Leads to a Disorder of N-Linked Glycosylation - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2427296/#:~:text=N,The%20human%20RFT1%20protein')
44. AnnotationURLCitation(end_index=13860, start_index=13746, title='Human RFT1 Deficiency Leads to a Disorder of N-Linked Glycosylation - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2427296/#:~:text=N,The%20human%20RFT1%20protein')
45. AnnotationURLCitation(end_index=14147, start_index=13997, title='Human RFT1 Deficiency Leads to a Disorder of N-Linked Glycosylation - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2427296/#:~:text=shares%2022,defect%20establishes%20the%20functional%20conservation')
46. AnnotationURLCitation(end_index=14505, start_index=14328, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=identified%20Rft1%20by%20yeast%20genetics,vitro%20flipping%20assay%20using%20proteoliposomes')
47. AnnotationURLCitation(end_index=14867, start_index=14753, title='Human RFT1 Deficiency Leads to a Disorder of N-Linked Glycosylation - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2427296/#:~:text=N,The%20human%20RFT1%20protein')
48. AnnotationURLCitation(end_index=15014, start_index=14868, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=topologically%20distinct,to%20the%20asparagine%20residue%20of')
49. AnnotationURLCitation(end_index=15361, start_index=15247, title='Human RFT1 Deficiency Leads to a Disorder of N-Linked Glycosylation - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2427296/#:~:text=N,The%20human%20RFT1%20protein')
50. AnnotationURLCitation(end_index=15537, start_index=15362, title='RFT1 Deficiency in Three Novel CDG Patients - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3869400/#:~:text=severe%20mental%20retardation%2C%20hypotonia%2C%20epilepsy%2C,was%20found%20in%20all%20four')
51. AnnotationURLCitation(end_index=15982, start_index=15817, title='Molecular characterization of Rft1, an ER membrane protein associated with congenital disorder of glycosylation RFT1-CDG - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11365447/#:~:text=the%20necessary%20glycosyltransferases%20are%20known%2C,glycosylation%20underlie')
52. AnnotationURLCitation(end_index=16279, start_index=16114, title='Molecular characterization of Rft1, an ER membrane protein associated with congenital disorder of glycosylation RFT1-CDG - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11365447/#:~:text=the%20necessary%20glycosyltransferases%20are%20known%2C,glycosylation%20underlie')
53. AnnotationURLCitation(end_index=16857, start_index=16742, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=complex,independent%20flippase')
54. AnnotationURLCitation(end_index=17032, start_index=16858, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=our%20results%20unequivocally%20support%20the,ER%20membrane%20during%20LLO%20biosynthesis')
55. AnnotationURLCitation(end_index=17749, start_index=17503, title='RFT1 Protein Affects Glycosylphosphatidylinositol (GPI) Anchor Glycosylation - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5247644/#:~:text=Skip%20to%20main%20content%20J,Serrano%20%5E%7B%E2%80%96%2C%7D%5E%7B%2A%2A%2C%7D%5E%7B1%7D%2C%20Peter%20B%C3%BCtikofer%20%5E%7B%E2%80%A1%2C%7D%5E%7B1%2C%7D%5E%7B2')
56. AnnotationURLCitation(end_index=18317, start_index=18203, title='Human RFT1 Deficiency Leads to a Disorder of N-Linked Glycosylation - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2427296/#:~:text=N,The%20human%20RFT1%20protein')
57. AnnotationURLCitation(end_index=18492, start_index=18318, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=our%20results%20unequivocally%20support%20the,ER%20membrane%20during%20LLO%20biosynthesis')
58. AnnotationURLCitation(end_index=18767, start_index=18641, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=studies%20identified%20Rft1%20as%20the,We')
59. AnnotationURLCitation(end_index=18945, start_index=18768, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=identified%20Rft1%20by%20yeast%20genetics,vitro%20flipping%20assay%20using%20proteoliposomes')
60. AnnotationURLCitation(end_index=19317, start_index=19140, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=identified%20Rft1%20by%20yeast%20genetics,vitro%20flipping%20assay%20using%20proteoliposomes')
61. AnnotationURLCitation(end_index=19432, start_index=19318, title='Human RFT1 Deficiency Leads to a Disorder of N-Linked Glycosylation - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2427296/#:~:text=N,The%20human%20RFT1%20protein')
62. AnnotationURLCitation(end_index=19958, start_index=19798, title='Does Rft1 flip an N-glycan lipid precursor? | Nature', type='url_citation', url='https://www.nature.com/articles/nature07165#:~:text=genetic%20evidence%20suggesting%20that%20Rft1%2C,itself%20remains%20to%20be%20identified')
63. AnnotationURLCitation(end_index=20309, start_index=20170, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=Dol,vitro%20flipping%20assay%20using%20proteoliposomes')
64. AnnotationURLCitation(end_index=20463, start_index=20310, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=match%20at%20L104%20yeast%20cells%2C,is%20not%20essential%20for%20at')
65. AnnotationURLCitation(end_index=20813, start_index=20667, title='Does Rft1 flip an N-glycan lipid precursor? | Nature', type='url_citation', url='https://www.nature.com/articles/nature07165#:~:text=that%20a%20specific%20ER%20protein,itself%20remains%20to%20be%20identified')
66. AnnotationURLCitation(end_index=21183, start_index=21026, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=yeast%20cells%2C%20in%20which%20Rft1,date%2C%20the%20identity%20of%20the')
67. AnnotationURLCitation(end_index=21552, start_index=21375, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=identified%20Rft1%20by%20yeast%20genetics,vitro%20flipping%20assay%20using%20proteoliposomes')
68. AnnotationURLCitation(end_index=21680, start_index=21553, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=match%20at%20L108%20flippase%20remains,Dol')
69. AnnotationURLCitation(end_index=22023, start_index=21877, title='Molecular characterization of Rft1, an ER membrane protein associated with congenital disorder of glycosylation RFT1-CDG - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11014557/#:~:text=is%20essential%20for%20the%20viability,termini%20facing%20the')
70. AnnotationURLCitation(end_index=22171, start_index=22024, title='Molecular characterization of Rft1, an ER membrane protein associated with congenital disorder of glycosylation RFT1-CDG - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11365447/#:~:text=including%20RFT1,a%20molecular%20characterization%20of%20human')
71. AnnotationURLCitation(end_index=22648, start_index=22474, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=our%20results%20unequivocally%20support%20the,ER%20membrane%20during%20LLO%20biosynthesis')
72. AnnotationURLCitation(end_index=23083, start_index=22968, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=complex,independent%20flippase')
73. AnnotationURLCitation(end_index=23411, start_index=23296, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=complex,independent%20flippase')
74. AnnotationURLCitation(end_index=23524, start_index=23412, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=f%29,independent%20flippase')
75. AnnotationURLCitation(end_index=24080, start_index=23915, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=of%20M5GN2%20to%20M3GN2%20after,lipid%20bilayer%20of%20reconstituted%20liposomes')
76. AnnotationURLCitation(end_index=24452, start_index=24287, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=of%20M5GN2%20to%20M3GN2%20after,lipid%20bilayer%20of%20reconstituted%20liposomes')
77. AnnotationURLCitation(end_index=24847, start_index=24682, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=of%20M5GN2%20to%20M3GN2%20after,lipid%20bilayer%20of%20reconstituted%20liposomes')
78. AnnotationURLCitation(end_index=25205, start_index=25031, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=our%20results%20unequivocally%20support%20the,ER%20membrane%20during%20LLO%20biosynthesis')
79. AnnotationURLCitation(end_index=25612, start_index=25483, title='Molecular characterization of Rft1, an ER membrane protein associated with congenital disorder of glycosylation RFT1-CDG - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11365447/#:~:text=including%20RFT1,its%20N%20and%20C%20termini')
80. AnnotationURLCitation(end_index=25773, start_index=25613, title='Molecular characterization of Rft1, an ER membrane protein associated with congenital disorder of glycosylation RFT1-CDG - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11365447/#:~:text=Rft1%2C%20using%20yeast%20cells%20as,work%20on%20this%20enigmatic%20protein')
81. AnnotationURLCitation(end_index=26100, start_index=25962, title='Molecular characterization of Rft1, an ER membrane protein associated with congenital disorder of glycosylation RFT1-CDG - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11014557/#:~:text=plays%20in%20N,work%20on%20this%20enigmatic%20protein')
82. AnnotationURLCitation(end_index=26432, start_index=26272, title='Molecular characterization of Rft1, an ER membrane protein associated with congenital disorder of glycosylation RFT1-CDG - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11014557/#:~:text=Both%20the%20AlphaFold2%20model%20and,MurJ%20lipid%20II%20flippases%20which')
83. AnnotationURLCitation(end_index=26572, start_index=26433, title='Molecular characterization of Rft1, an ER membrane protein associated with congenital disorder of glycosylation RFT1-CDG - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11014557/#:~:text=match%20at%20L595%20potenqal%20%2858%E2%80%9361%29,Fig')
84. AnnotationURLCitation(end_index=27046, start_index=26907, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=Dol,vitro%20flipping%20assay%20using%20proteoliposomes')
85. AnnotationURLCitation(end_index=27162, start_index=27047, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=complex,independent%20flippase')
86. AnnotationURLCitation(end_index=27510, start_index=27336, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=our%20results%20unequivocally%20support%20the,ER%20membrane%20during%20LLO%20biosynthesis')
87. AnnotationURLCitation(end_index=27667, start_index=27511, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=translocation%20and%20demonstrate%20that%20purified,Dol%20ER%20flippase')
88. AnnotationURLCitation(end_index=28027, start_index=27871, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=translocation%20and%20demonstrate%20that%20purified,Dol%20ER%20flippase')
89. AnnotationURLCitation(end_index=28202, start_index=28028, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=our%20results%20unequivocally%20support%20the,ER%20membrane%20during%20LLO%20biosynthesis')
90. AnnotationURLCitation(end_index=28595, start_index=28422, title='Human RFT1 Deficiency Leads to a Disorder of N-Linked Glycosylation - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2427296/#:~:text=series%20of%20ordered%20reactions%20requiring,the%20low%20sequence%20similarity%20between')
91. AnnotationURLCitation(end_index=28754, start_index=28596, title='RFT1 Deficiency in Three Novel CDG Patients - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3869400/#:~:text=match%20at%20L35%20protein,earlier%20reported%20RFT1%20missense%20mutation')
92. AnnotationURLCitation(end_index=29093, start_index=28920, title='Human RFT1 Deficiency Leads to a Disorder of N-Linked Glycosylation - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2427296/#:~:text=series%20of%20ordered%20reactions%20requiring,the%20low%20sequence%20similarity%20between')
93. AnnotationURLCitation(end_index=29468, start_index=29354, title='Human RFT1 Deficiency Leads to a Disorder of N-Linked Glycosylation - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2427296/#:~:text=N,The%20human%20RFT1%20protein')
94. AnnotationURLCitation(end_index=29753, start_index=29603, title='Human RFT1 Deficiency Leads to a Disorder of N-Linked Glycosylation - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2427296/#:~:text=shares%2022,defect%20establishes%20the%20functional%20conservation')
95. AnnotationURLCitation(end_index=30166, start_index=29991, title='RFT1 Deficiency in Three Novel CDG Patients - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3869400/#:~:text=protein.%20Recently%2C%20the%20first%20RFT1,earlier%20reported%20RFT1%20missense%20mutation')
96. AnnotationURLCitation(end_index=30308, start_index=30167, title='RFT1 Deficiency in Three Novel CDG Patients - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3869400/#:~:text=match%20at%20L99%20for%20RFT1,Jaeken%20et%20al.%2C%202008')
97. AnnotationURLCitation(end_index=30623, start_index=30448, title='RFT1 Deficiency in Three Novel CDG Patients - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3869400/#:~:text=protein.%20Recently%2C%20the%20first%20RFT1,earlier%20reported%20RFT1%20missense%20mutation')
98. AnnotationURLCitation(end_index=31048, start_index=30873, title='RFT1 Deficiency in Three Novel CDG Patients - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3869400/#:~:text=severe%20mental%20retardation%2C%20hypotonia%2C%20epilepsy%2C,was%20found%20in%20all%20four')
99. AnnotationURLCitation(end_index=31328, start_index=31153, title='RFT1 Deficiency in Three Novel CDG Patients - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3869400/#:~:text=severe%20mental%20retardation%2C%20hypotonia%2C%20epilepsy%2C,was%20found%20in%20all%20four')
100. AnnotationURLCitation(end_index=31685, start_index=31510, title='RFT1 Deficiency in Three Novel CDG Patients - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3869400/#:~:text=severe%20mental%20retardation%2C%20hypotonia%2C%20epilepsy%2C,was%20found%20in%20all%20four')
101. AnnotationURLCitation(end_index=32010, start_index=31835, title='RFT1 Deficiency in Three Novel CDG Patients - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3869400/#:~:text=severe%20mental%20retardation%2C%20hypotonia%2C%20epilepsy%2C,was%20found%20in%20all%20four')
102. AnnotationURLCitation(end_index=32172, start_index=32011, title='RFT1 Deficiency in Three Novel CDG Patients - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3869400/#:~:text=phenotype%20of%20these%20patients%20comprised,crucial%20role%20of%20RFT1%20in')
103. AnnotationURLCitation(end_index=32548, start_index=32387, title='RFT1 Deficiency in Three Novel CDG Patients - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3869400/#:~:text=phenotype%20of%20these%20patients%20comprised,crucial%20role%20of%20RFT1%20in')
104. AnnotationURLCitation(end_index=32718, start_index=32549, title='RFT1 Deficiency in Three Novel CDG Patients - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3869400/#:~:text=comparison%20to%20other%20CDG%20defects%2C,because%20deafness%20has%20been%20reported')
105. AnnotationURLCitation(end_index=33004, start_index=32843, title='RFT1 Deficiency in Three Novel CDG Patients - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3869400/#:~:text=phenotype%20of%20these%20patients%20comprised,crucial%20role%20of%20RFT1%20in')
106. AnnotationURLCitation(end_index=33174, start_index=33005, title='RFT1 Deficiency in Three Novel CDG Patients - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3869400/#:~:text=comparison%20to%20other%20CDG%20defects%2C,because%20deafness%20has%20been%20reported')
107. AnnotationURLCitation(end_index=33579, start_index=33404, title='RFT1 Deficiency in Three Novel CDG Patients - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3869400/#:~:text=severe%20mental%20retardation%2C%20hypotonia%2C%20epilepsy%2C,was%20found%20in%20all%20four')
108. AnnotationURLCitation(end_index=33922, start_index=33790, title='RFT1-congenital disorder of glycosylation - NIH Genetic Testing Registry (GTR) - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gtr/conditions/C2677590#:~:text=Warning%3A%20The%20NCBI%20web%20site,Orphanet')
109. AnnotationURLCitation(end_index=34329, start_index=34164, title='Molecular characterization of Rft1, an ER membrane protein associated with congenital disorder of glycosylation RFT1-CDG - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11365447/#:~:text=numerous%20human%20genetic%20disorders%20including,glycoproteins%20in%20the%20ER')
110. AnnotationURLCitation(end_index=34718, start_index=34604, title='Human RFT1 Deficiency Leads to a Disorder of N-Linked Glycosylation - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2427296/#:~:text=N,The%20human%20RFT1%20protein')
111. AnnotationURLCitation(end_index=34892, start_index=34719, title='Human RFT1 Deficiency Leads to a Disorder of N-Linked Glycosylation - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2427296/#:~:text=series%20of%20ordered%20reactions%20requiring,the%20low%20sequence%20similarity%20between')
112. AnnotationURLCitation(end_index=35445, start_index=35270, title='RFT1 Deficiency in Three Novel CDG Patients - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3869400/#:~:text=Congenital%20disorders%20of%20glycosylation%20,sialotransferrin%20pattern%20is%20the%20most')
113. AnnotationURLCitation(end_index=35953, start_index=35803, title='Human RFT1 Deficiency Leads to a Disorder of N-Linked Glycosylation - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2427296/#:~:text=shares%2022,defect%20establishes%20the%20functional%20conservation')
114. AnnotationURLCitation(end_index=36259, start_index=36077, title='Human RFT1 Deficiency Leads to a Disorder of N-Linked Glycosylation - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2427296/#:~:text=orthology%20and%20the%20pathologic%20effect,defect%20establishes%20the%20functional%20conservation')
115. AnnotationURLCitation(end_index=37168, start_index=36993, title='RFT1 Deficiency in Three Novel CDG Patients - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3869400/#:~:text=Congenital%20disorders%20of%20glycosylation%20,sialotransferrin%20pattern%20is%20the%20most')
116. AnnotationURLCitation(end_index=37584, start_index=37469, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=complex,independent%20flippase')
117. AnnotationURLCitation(end_index=38201, start_index=38062, title='Molecular characterization of Rft1, an ER membrane protein associated with congenital disorder of glycosylation RFT1-CDG - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11014557/#:~:text=match%20at%20L595%20potenqal%20%2858%E2%80%9361%29,Fig')
118. AnnotationURLCitation(end_index=39110, start_index=38945, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=of%20M5GN2%20to%20M3GN2%20after,lipid%20bilayer%20of%20reconstituted%20liposomes')
119. AnnotationURLCitation(end_index=40875, start_index=40701, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=our%20results%20unequivocally%20support%20the,ER%20membrane%20during%20LLO%20biosynthesis')
120. AnnotationURLCitation(end_index=41338, start_index=41164, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=our%20results%20unequivocally%20support%20the,ER%20membrane%20during%20LLO%20biosynthesis')
121. AnnotationURLCitation(end_index=41590, start_index=41430, title='Molecular characterization of Rft1, an ER membrane protein associated with congenital disorder of glycosylation RFT1-CDG - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11014557/#:~:text=Both%20the%20AlphaFold2%20model%20and,MurJ%20lipid%20II%20flippases%20which')
122. AnnotationURLCitation(end_index=41751, start_index=41591, title='Molecular characterization of Rft1, an ER membrane protein associated with congenital disorder of glycosylation RFT1-CDG - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11365447/#:~:text=Rft1%2C%20using%20yeast%20cells%20as,work%20on%20this%20enigmatic%20protein')
123. AnnotationURLCitation(end_index=42032, start_index=41855, title='Rft1 catalyzes lipid-linked oligosaccharide translocation across the ER membrane - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11182771/#:~:text=identified%20Rft1%20by%20yeast%20genetics,vitro%20flipping%20assay%20using%20proteoliposomes')
124. AnnotationURLCitation(end_index=42296, start_index=42123, title='Human RFT1 Deficiency Leads to a Disorder of N-Linked Glycosylation - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2427296/#:~:text=series%20of%20ordered%20reactions%20requiring,the%20low%20sequence%20similarity%20between')
125. AnnotationURLCitation(end_index=42538, start_index=42378, title='Does Rft1 flip an N-glycan lipid precursor? | Nature', type='url_citation', url='https://www.nature.com/articles/nature07165#:~:text=genetic%20evidence%20suggesting%20that%20Rft1%2C,itself%20remains%20to%20be%20identified')